Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Growth & Development clinical trials

1 of 3 indexed Growth & Development trials are currently recruiting.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Growth & Development: 3 US clinical trials tracked, 1 recruiting.

Growth & Development is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is The Hospital for Sick Children, running 1 of these trials.

Enrollment posture brief

Registry condition growth-development

OPEN 1 | RECR 33% | LATE 0 | EARLY 0 | RANK #5209 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Growth & Development (this)33%
Open-enrollment share among volume-matched conditions near Growth & Development

Growth & Development lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Growth & Development on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Growth & Development is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Growth & Development records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Infant egg consumption (i.e., age of introduction and frequency of intake) Other
1 trials
performance feedback with an educational module Procedure
1 trials
Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study. Other
1 trials

US sites by state

Facility locations filed on Growth & Development trials. A trial with sites in several states counts in each.

New York 1 trials
Missouri 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Growth & Development page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Growth & Development condition card totals 3 registered trials; most-linked intervention Infant egg consumption (i.e., age of introduction and frequency of intake); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.